Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ProQR Therapeutics N.V. (0PQ.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
1.4255+0.0605 (+4.43%)
At close: 09:57PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3650
Open1.3745
Bid1.3745 x 50000
Ask1.4255 x 50000
Day's Range1.3190 - 1.4795
52 Week Range0.5190 - 7.4500
Volume13,935
Avg. Volume4,017
Market Cap105.075M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    ProQR Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

    ProQR Therapeutics ( NASDAQ:PRQR ) Third Quarter 2022 Results Key Financial Results Net loss: €24.4m (loss widened by...

  • Zacks

    ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of -47.83% and 7.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Raymond James Bullish On This Penny Stock's Reprioritized Pipeline

    Raymond James upgraded ProQR Therapeutics N.V. (NASDAQ: PRQR) to Outperform based on a high conviction that "RNA editing" emerges as an impactful field of therapeutics in coming years. Related: This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing. The analyst notes that targets are plentiful, including Alpha-1-antitrypsin deficiency, on which Raymond James based the new model (assume this will be one of five programs partnered with Eli Lilly And Co (NYSE: LLY) with peak royalt

Advertisement
Advertisement